Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. However, the overall efficacies of TKIs are limited due to the development of drug resistance. Therefore, it is important...

Descripción completa

Detalles Bibliográficos
Autores principales: Botting, Gregory M., Rastogi, Ichwaku, Chhabra, Gagan, Nlend, Marie, Puri, Neelu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547756/
https://www.ncbi.nlm.nih.gov/pubmed/26301867
http://dx.doi.org/10.1371/journal.pone.0136155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547756/
https://www.ncbi.nlm.nih.gov/pubmed/26301867
http://dx.doi.org/10.1371/journal.pone.0136155

Ejemplares similares